Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

Vaishali Sanchorawala, MD, Gheorghe Doros, Karen Quillen, MD, MPH, John Mark Sloan, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Kathleen T Finn, ANP, David C Seldin, MD, PhD

Blood (2013) 122 (21): 3328.

https://doi.org/10.1182/blood.V122.21.3328.3328

Published: 2013

Journal Articles

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Stephanie B. Tsai, David C. Seldin, Karen Quillen, John L. Berk, Frederick L. Ruberg, Hans Meier-Ewert, J. Mark Sloan, Gheorghe Doros, Kathleen T. Finn, Martha Skinner, Vaishali Sanchorawala

Blood (2012) 120 (22): 4445–4446.

https://doi.org/10.1182/blood-2012-09-457341

Published: 2012

Journal Articles

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Divya Nair, MD, Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Salli A Fennessey, Kathleen T Finn, ANP, Martha Skinner, MD, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 4084.

https://doi.org/10.1182/blood.V120.21.4084.4084

Published: 2012

Journal Articles

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115

Vaishali Sanchorawala, MD, Antje Hoering, PhD, David C Seldin, MD, PhD, Kathleen T Finn, ANP, Salli A Fennessey, Bassam I Mattar, MD, Hana F Safah, MD, Leona Holmberg, MD, PhD, Robert M. Dean, MD, Robert Z. Orlowski, MD, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 2004.

https://doi.org/10.1182/blood.V118.21.2004.2004

Published: 2011

Journal Articles

Melphalan, Lenalidomide and Dexamethasone Combination Therapy In Patients with AL Amyloidosis

Jaymin Patel, MD, John Mark Sloan, MD, Anthony C Shelton, RN, Kathleen T Finn, ANP, Vaishali Sanchorawala, MD

Blood (2011) 118 (21): 2924.

https://doi.org/10.1182/blood.V118.21.2924.2924

Published: 2011

Journal Articles

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Maria Teresa Cibeira, Vaishali Sanchorawala, David C. Seldin, Karen Quillen, John L. Berk, Laura M. Dember, Adam Segal, Frederick Ruberg, Hans Meier-Ewert, Nancy T. Andrea, J. Mark Sloan, Kathleen T. Finn, Gheorghe Doros, Joan Blade, Martha Skinner

Blood (2011) 118 (16): 4346–4352.

https://doi.org/10.1182/blood-2011-01-330738

Published: 2011

Journal Articles

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

Umit Tapan, David C. Seldin, Kathleen T. Finn, Salli Fennessey, Anthony Shelton, Jerome B. Zeldis, Vaishali Sanchorawala

Blood (2010) 116 (23): 5071–5072.

https://doi.org/10.1182/blood-2010-09-305136

Published: 2010

Journal Articles

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

M. Teresa Cibeira, MD, PhD, Vaishali Sanchorawala, MD, David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy Andrea, MD, J. Mark Sloan, MD, Kathleen T Finn, ANP, John L Berk, MD, Gheorghe Doros, PhD, Joan Blade, Martha Skinner, MD

Blood (2010) 116 (21): 2394.

https://doi.org/10.1182/blood.V116.21.2394.2394

Published: 2010

Journal Articles

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Vaishali Sanchorawala, MD, Karen Quillen, MD, MPH, Kathleen T Finn, ANP, Nancy T Andrea, MD, J. Mark Sloan, MD, Laura Dember, MD, Adam Segal, MD, Gheorghe Doros, PhD, Martha Skinner, MD, David Seldin, MD

Blood (2010) 116 (21): 3553.

https://doi.org/10.1182/blood.V116.21.3553.3553

Published: 2010

Journal Articles

Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis

Umit Tapan, MD, David C Seldin, MD, PhD, Kathleen T Finn, ANP, Salli Fennessey, CRA, Anthony C Shelton, RN, Jerome B. Zeldis, MD, PhD, Vaishali Sanchorawala, MD

Blood (2010) 116 (21): 3021.

https://doi.org/10.1182/blood.V116.21.3021.3021

Published: 2010

Journal Articles

Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis

Vaishali Sanchorawala, MD, Kathleen T Finn, ANP, Salli Fennessey, CRA, Anthony C Shelton, RN, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2010) 116 (21): 3022.

https://doi.org/10.1182/blood.V116.21.3022.3022

Published: 2010

Journal Articles

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

Vaishali Sanchorawala, Kathleen T. Finn, Salli Fennessey, Anthony Shelton, Gheorghe Doros, Jerome B. Zeldis, David C. Seldin

Blood (2010) 116 (11): 1990–1991.

https://doi.org/10.1182/blood-2010-07-295485

Published: 2010

Journal Articles

Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis.

Karen Quillen, MD, David C. Seldin, MD, PhD, Kathleen T. Finn, RN, ANP, AOCN, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 2318.

https://doi.org/10.1182/blood.V114.22.2318.2318

Published: 2009

Journal Articles

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.

Saulius Girnius, MD, Frank Tsai, MD, David C. Seldin, MD, PhD, Karen Quillen, MD, Lisa Yanarella, NP, Kathleen T. Finn, NP, Nancy T. Andrea, MD, John Mark Sloan, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 4352.

https://doi.org/10.1182/blood.V114.22.4352.4352

Published: 2009

Journal Articles

Bortezomib and High Dose Melphalan Followed by Autologous Stem Cell Transplantation (BortHDM/SCT) for the Treatment of AL Amyloidosis: Results of a Feasibility Study.

Vaishali Sanchorawala, MD, Lisa Yanarella, NP, Karen Quillen, MD, John Mark Sloan, MD, Nancy T. Andrea, MD, Kathleen T. Finn, NP, David C. Seldin, MD, PhD

Blood (2009) 114 (22): 4353.

https://doi.org/10.1182/blood.V114.22.4353.4353

Published: 2009

Journal Articles

Long Term Results of High-Dose Melphalan and Autologous Stem Cell Transplantation in Non-Amyloid Monoclonal Immunoglobulin Deposition Disorders.

Saulius Girnius, MD, David C. Seldin, MD, PhD, Karen Quillen, MD, Kathleen T. Finn, NP, Nancy T. Andrea, MD, John Mark Sloan, MD, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 4356.

https://doi.org/10.1182/blood.V114.22.4356.4356

Published: 2009

Journal Articles

Melphalan, Lenalidomide, and Dexamethasone Combination Therapy in Patients with AL Amyloidosis.

John Mark Sloan, MD, Vaishali Sanchorawala, MD, Saulius Girnius, M.D., Kathleen T. Finn, NP, David C. Seldin, MD, PhD

Blood (2009) 114 (22): 1859.

https://doi.org/10.1182/blood.V114.22.1859.1859

Published: 2009

Journal Articles

Treatment-Related Mortality in Patients with AL Amyloidosis Undergoing High-Dose Melphalan and Stem Cell Transplantation: Trend Over the Past 14 Years at a Single Institution

Vaishali Sanchorawala, MD, Martha Skinner, Kathleen T. Finn, Karen Quillen, David C. Seldin

Blood (2008) 112 (11): 53.

https://doi.org/10.1182/blood.V112.11.53.53

Published: 2008

Journal Articles

Febrile Reactions Occurring with Second Cycle of High Dose Melphalan and Stem Cell Transplantation in Patients with AL Amyloidosis: A “Melphalan Recall” Reaction.

Michael Rosenzweig, David C. Seldin, Daniel G Remick, Martha Skinner, Karen Quillen, Betul Oran, Kathleen T. Finn, Vaishali Sanchorawala

Blood (2008) 112 (11): 1120.

https://doi.org/10.1182/blood.V112.11.1120.1120

Published: 2008

Journal Articles

Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.

David C. Seldin, MD, PhD, Michael Rosenzweig, MD, Kathleen T. Finn, RN, NP, Salli Fennessey, Anthony Shelton, Jerome B. Zeldis, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2007) 110 (11): 192.

https://doi.org/10.1182/blood.V110.11.192.192

Published: 2007

NARROW

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115

Melphalan, Lenalidomide and Dexamethasone Combination Therapy In Patients with AL Amyloidosis

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis

Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis.

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.

Bortezomib and High Dose Melphalan Followed by Autologous Stem Cell Transplantation (BortHDM/SCT) for the Treatment of AL Amyloidosis: Results of a Feasibility Study.

Long Term Results of High-Dose Melphalan and Autologous Stem Cell Transplantation in Non-Amyloid Monoclonal Immunoglobulin Deposition Disorders.

Melphalan, Lenalidomide, and Dexamethasone Combination Therapy in Patients with AL Amyloidosis.

Treatment-Related Mortality in Patients with AL Amyloidosis Undergoing High-Dose Melphalan and Stem Cell Transplantation: Trend Over the Past 14 Years at a Single Institution

Febrile Reactions Occurring with Second Cycle of High Dose Melphalan and Stem Cell Transplantation in Patients with AL Amyloidosis: A “Melphalan Recall” Reaction.

Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only